VARIPULSE BI-DIRECTIONAL CATHETER
Biosense Webster, Inc. · Decision date Sep 15, 2026
What did the FDA decide?
The FDA record for P240006/S020 lists the VARIPULSE BI-DIRECTIONAL CATHETER, a percutaneous cardiac ablation catheter for atrial fibrillation using irreversible electroporation, filed by Biosense Webster, Inc. under product code QZI. The decision is recorded as OK30, dated 2026-09-15, with supplement type 30-Day Notice and reason Process Change - Manufacturer/Sterilizer/Packager/Supplier.
The stated purpose is 'an additional supplier for critical components.' That describes a change to the supply chain of components rather than a new version of the whole system. The record does not name the component, the added supplier, the affected manufacturing site, or any qualification or validation work. The supplement identifier ties the notice to the original PMA P240006; the stated purpose does not show safety or clinical effectiveness for any use.
Because the entry is a 30-day notice, researchers should read OK30 as the database's disposition code for this filing; it is not an original PMA approval of the catheter.
FDA approval order statement
an additional supplier for critical components
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 15, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240006/S020
- Regulatory pathway
- PMA supplement
- Applicant
- Biosense Webster, Inc.
- Product code
- QZI
- Decision code
- OK30
- Decision date
- Sep 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Biosense Webster, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240006. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240006 · Original PMA
VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)
P240006/S020 received
Application receipt date recorded by FDA.
P240006/S019 · Related supplement
VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)
P240006/S020 · FDA decision
30-Day Notice
P240006/S018 · Related supplement
Varipulse Bi-Directional Catheter
Timeline entries are records held by MedtechLedger for P240006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA approval | Nov 6, 2024 | FDA | |
| Biosense Webster, Inc. | PMA supplement | Sep 10, 2026 | FDA | |
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biosense Webster, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 91618
Sources and methodology
- Original FDA record: P240006/S020
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
